Aptus Pharma Ltd.

As of March 31, 2026, Aptus Pharma Ltd. carries a market capitalization of 2.40B, placing it among publicly traded companies globally. Its enterprise value stands at 2.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Aptus Pharma Ltd. has 17.15M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Aptus Pharma Ltd. maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Aptus Pharma Ltd. recorded 11.50M in income tax expense.

As of the close on October 22, 2026, Aptus Pharma Ltd.'s stock has gained approximately 907.35% over the past 52 weeks. The 50-day moving average sits at 351.22, while the 200-day moving average is 207.51.

As of March 31, 2026, Aptus Pharma Ltd. holds 10.27M in cash and equivalents against 71.82M in total debt, resulting in a net debt position of 61.55M. Total book value stands at 233.46M, with working capital of 159.30M providing operational flexibility.

Aptus Pharma Ltd.'s most recent stock split took place on May 12, 2026 with a 2:5 split ratio.